Chemomab to Present Late-Breaking Phase 2 Results of CM-101 for PSC at AASLD 2024

Chemomab Therapeutics Ltd. recently revealed that a late breaking abstract on the Phase 2 SPRING trial results for primary sclerosing cholangitis (PSC) will be presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. This event is scheduled to be held in San Diego, California, from November 15 to 19, 2024.

The oral presentation will be delivered by Professor Christopher Bowlus, MD, FAASLD, who holds the Lena Valente Professorship and serves as Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. Professor Bowlus will discuss the findings from the double-blinded segment of the Phase 2 SPRING trial, which investigated the effects of CM-101 on patients with PSC. The study is titled "CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study". The presentation is scheduled for November 18, 2024, from 2:45 PM to 3:00 PM PST, as part of the Late Breaking Abstract Parallel Session 1.

Executives from Chemomab’s senior leadership will attend the conference. They will be available for meetings and to provide more details about the company's progress and future plans.

Chemomab Therapeutics Ltd. is a biotechnology firm focused on developing novel treatments for fibro-inflammatory diseases that currently have limited treatment options. The company's lead product, CM-101, is a monoclonal antibody that targets the soluble protein CCL24, which plays a key role in driving fibrosis and inflammation. CM-101's dual activity has shown promise in both clinical and preclinical trials, demonstrating a good safety profile and tolerability. This therapeutic has the potential to address several severe and life-threatening fibro-inflammatory conditions.

The company has reported positive outcomes from four clinical trials involving CM-101 in patients. Notably, the Phase 2 trial for PSC has yielded encouraging results, prompting the company to anticipate two significant milestones in early 2025. These include receiving feedback from the FDA regarding the design of a planned Phase 3 registrational trial for PSC. CM-101 has obtained Orphan Drug and Fast Track designations from the FDA, as well as Orphan Drug designation from the EMA for PSC. Additionally, Chemomab’s CM-101 program for systemic sclerosis is ready for Phase 2, with an open Investigational New Drug (IND) application filed in the U.S.

Chemomab continues to focus on the development and potential commercialization of CM-101, aiming to address unmet medical needs in fibro-inflammatory diseases.